Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of France's Theravia for an undisclosed sum.

Norgine's acquisition of Theravia enhances its rare disease pharmaceutical offerings, broadening access to innovative treatments across Europe.

Norgine has made a significant move by acquiring Theravia, expanding its rare disease portfolio. This acquisition positions Norgine as a leading partner in the specialty pharma market.

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...

Disclosures. Ware:Nova Laboratories: Other: Medical Advisory Board; Theravia: Other: Medical Advisory Board; Merck Pharmaceuticals: Other: Medical Advisory

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising rare and spe...

Norgine has successfully acquired Theravia, enhancing its capabilities in rare disease therapies and expanding its reach to underserved patient populations.

Norgine has announced the successful acquisition of Theravia, enhancing its portfolio in rare diseases and improving treatment options for patients.

Norgine has completed the acquisition of Theravia, a move aimed at enhancing their portfolio in rare disease therapies and addressing high unmet medical needs.

Norgine has finalized the acquisition of Theravia, significantly enhancing its portfolio targeting rare disease treatments and expanding patient access across markets.

Norgine has finalized its acquisition of Theravia, aiming to strengthen its portfolio of therapies for rare diseases and enhance patient access to vital medications.

Le laboratoire pharmaceutique nééerlandais Norgine a annoncé dans un communiqué le 14 août la finalisation de l'acquisition du laboratoire français Theravia spécialisé dans le développement de thérapies dans le domaine des maladies rares. Les deux entreprises avaient annoncé avoir signé

PARIS, 14 de agosto de 2025 /PRNewswire/ -- Norgine anunció hoy la exitosa adquisición de Theravia, compañía farmacéutica internacional especializada en terapias para pacientes con enfermedades raras y debilitantes. El cierre de esta adquisición representa un gran paso adelante para que...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine’s strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transac...

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in t...

PARIS, Aug. 14, 2025 /PRNewswire/ — Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for patients with rare and debilitating conditions. The closure of this acquisition marks a major step forward for Norgine to deliver on its ambition to bring life-changing medicines to patients with high …